2026: Top 10 Medical Devices Companies

Why Medical Devices Market Are Expanding?

The Medical Devices Market is experiencing sustained structural growth, rising from USD 688.18 billion in 2025 to a projected USD 1,377.54 billion by 2035, registering a CAGR of 7.21% during the 2025–2035 forecast period. Market Research Future (MRFR) identifies two converging forces driving this expansion: the accelerating global burden of chronic and age-related diseases, and the rapid integration of artificial intelligence, robotics, and connected-sensor technologies into clinical diagnostics and therapeutic workflows across hospital and home-care settings.

Diagnostic devices represent the largest application sector, with 56% of market share in 2025, driven by imaging, laboratory tests, and point-of-care devices embedded in hospital diagnostic pathways globally. Therapeutic devices are the fastest expanding segment, benefiting from the desire for minimally invasive interventional treatments in cardiology, orthopedic and neurological care. Hospitals, the end user, represent 62 percent of the market revenue, while home-care settings at 21 percent are growing fast as remote patient monitoring and wearable diagnostics minimize the need for inpatient visits.

Why These Companies Are Leading the Market?

Market Research Future (MRFR) identifies four structural factors separating category leaders in the Medical Devices Market: platform breadth and portfolio diversification across device categories, technology differentiation through AI integration and robotic-assisted surgery, global regulatory and commercial infrastructure, and disciplined M&A strategy to access high-growth adjacencies and deepen segment leadership.

Portfolio breadth defines the largest revenue holders. Medtronic plc integrates cardiac rhythm management, neuromodulation, surgical robotics, and diabetes monitoring into a single global commercial infrastructure spanning 150+ countries, providing hospitals with a preferred vendor relationship across multiple therapeutic categories. Technology differentiation is exemplified by Siemens Healthineers, whose AI-Rad Companion platform applies machine learning to imaging interpretation across 20+ clinical applications, reducing radiologist read times and improving diagnostic accuracy in oncology and cardiovascular screening.

MRFR assesses that the defining characteristic of a category leader in this market is the ability to deliver an integrated clinical and commercial value proposition — spanning diagnostics, intervention, monitoring, and outcomes data — within a single enterprise relationship. Vendors unable to demonstrate clinical workflow integration and evidence-based outcomes improvement will face margin compression as payer-mandated value-based care models expand across North America, Europe, and high-growth Asia-Pacific markets.

Top 10 Global Medical Devices Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading medical device companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

*Rankings based on MRFR analysis. Revenue figures sourced from official company filings, investor relations disclosures, and analyst estimates. CAGR reflects company-guided or analyst-estimated growth for medical device-relevant segments.

Detailed Company Profiles

1. Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic plc is the world’s largest pure-play medical device firm, with four reporting segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio and Diabetes Operating Unit. The company’s Cardiovascular sector includes cardiac rhythm management, structural heart and coronary interventional devices, while its Neuroscience portfolio includes spinal, neurovascular and neuromodulation therapies. Medtronic services hospitals, integrated health systems and ambulatory care centers in more than 150 countries and employs over 95,000 people worldwide.

2. Johnson & Johnson MedTech | NYSE: JNJ | New Brunswick, New Jersey, USA

Johnson & Johnson MedTech is one of the broadest-portfolio medical device companies globally, operating across six strategic franchises: Cardiovascular, Surgery, Vision, Orthopaedics, MedTech AI & Digital Surgery, and Neurovascular. The MedTech segment generated approximately USD 33.8 billion in FY2025 revenue, representing approximately 36% of Johnson & Johnson's total USD 94.2 billion enterprise revenue. J&J MedTech serves over 1 billion patients globally and holds leading market positions in electrophysiology, surgical robotics, intraocular lenses, and total joint replacement.

3. Abbott Laboratories | NYSE: ABT | Abbott Park, Illinois, USA

Abbott Laboratories is a diverse medical device company with products in four segments: Established Pharmaceuticals, Diagnostics, Medical Devices and Nutritional Products. The Medical Devices sector, Abbott’s largest revenue generator, comprises cardiovascular devices, neuromodulation therapies, and the FreeStyle Libre continuous glucose monitoring system, the top CGM platform globally by installed base. Abbott has roughly 114,000 employees worldwide and serves patients and customers in over 160 countries.

4. Siemens Healthineers AG | XETRA: SHL | Erlangen, Germany

Siemens Healthineers AG is a prominent medical technology firm in the world, providing diagnostic imaging, laboratory diagnostics, point-of-care testing and digital health solutions. The company’s imaging portfolio includes MRI, CT, PET, X-ray and ultrasound equipment, used in around 70 countries and over 5 million patients each day. Siemens Healthineers’ AI-Rad Companion platform uses FDA-cleared machine learning algorithms to automate measurement, detection and reporting in radiology and pathology processes for 20+ clinical applications.

5. Stryker Corporation | NYSE: SYK | Kalamazoo, Michigan, USA

About Stryker Corporation Stryker Corporation is a Fortune 500 medical technology firm that offers two segments: MedSurg & Neurotechnology and Orthopaedics & Spine. The company’s Mako™ robotic-arm assisted surgery system has become the market-leading platform for total knee and total hip arthroplasty with more than 2 million procedures completed worldwide. Stryker’s MedSurg business offers surgical equipment, endoscopy systems, and emergency medical equipment. The Neurotechnology sector offers stroke intervention, brain monitoring, and ENT surgery. It employs more than 53,000 people and has a presence in over 100 countries.

6. GE HealthCare Technologies Inc. | NASDAQ: GEHC | Chicago, Illinois, USA

GE HealthCare Technologies is a global leader in medical imaging, patient monitoring and health information technology, providing MRI, CT, PET, X-ray and ultrasound devices and clinical decision support software powered by AI through its Edison™ health platform. The company's Patient Care Solutions division markets monitoring, anesthetic and maternal-infant care devices for ICUs, operating rooms and ambulatory settings in more than 160 countries. Diagnostic imaging, which accounts for around 65% of total company sales, is the main revenue driver for GE HealthCare’s Imaging sector.

7. Boston Scientific Corporation | NYSE: BSX | Marlborough, Massachusetts, USA

Boston Scientific is a global medical technology leader dedicated to developing less invasive solutions for the treatment of coronary artery disease, rhythm management, intervention radiology and urology. The company’s Electrophysiology franchise, centered on the FARAPULSE™ pulsed field ablation equipment, is its fastest growing division to help address the atrial fibrillation ablation market. Boston Scientific provides service to physicians treating difficult cardiovascular, neurological, urological and gastrointestinal illnesses in more than 130 countries.

8. Becton, Dickinson and Company | NYSE: BDX | Franklin Lakes, New Jersey, USA

Becton, Dickinson and firm (BD) is a multinational medical technology firm with three segments: BD Medical (drug administration, infusion therapy), BD Diagnostics (specimen collection, microbiology, molecular diagnostics) and BD Life Sciences (flow cytometry, research reagents). BD’s MedSurge business makes catheters, syringes, insulin delivery pens and infusion pumps used in more than 190 countries around the world, making BD the most geographically diverse medical device firm in the world. The company services hospitals, laboratories, clinics and government health ministries in all major markets.

9. Fresenius SE & Co. KGaA | XETRA: FRE | Bad Homburg, Germany

Fresenius SE & Co. KGaA is a global healthcare group, whose medical device business is primarily represented by Fresenius Kabi. Fresenius Kabi develops and manufactures infusion therapy products, clinical nutrition delivery systems, IV generic pharmaceuticals and biosimilar biologics for hospital and outpatient use. Fresenius Kabi’s device portfolio includes infusion pumps, IV containers, enteral feeding systems and medication delivery accessories used in critical care, cancer and nutrition support environments in 100+ countries. The segment has around 41,580 employees worldwide.

10. Philips (Koninklijke Philips N.V.) | ENXTAM: PHIA | Amsterdam, Netherlands

Koninklijke Philips N.V. is a health technology company focused on diagnostic imaging, patient monitoring, connected care software, and sleep and respiratory care devices. Philips' Diagnosis & Treatment businesses deliver MRI, CT, and ultrasound systems alongside interventional X-ray platforms for cardiovascular and oncological procedures. Its Connected Care division provides enterprise patient monitoring, telehealth, and hospital command center solutions to integrated health systems across 100+ countries.

M&A Activity Tracker (2023–2026)

The Medical Devices Market has experienced significant consolidation as platform leaders pursue inorganic growth to access high-growth clinical adjacencies in electrophysiology, robotic surgery, neurovascular intervention, and connected diagnostics, while private equity and strategic buyers recognize the recurring revenue characteristics of procedure-enabling device platforms. Market Research Future tracks the following verified transactions directly relevant to the medical devices market:

Key Trend: MRFR analysis identifies cardiovascular platform expansion — particularly into electrophysiology, mechanical thrombectomy, and structural heart intervention — as the dominant M&A theme across 2023–2026, as device companies compete to own the full procedural workflow for cardiac and vascular disease management.

R&D Investment & Innovation Signals

R&D investment across the Medical Devices Market has increased materially in 2025–2026 as vendors race to integrate AI-assisted diagnostics, pulsed field ablation energy sources, and robotic-assisted surgical platforms — addressing the primary technical and clinical barriers to next-generation procedural adoption. Market Research Future tracks the following verified 2025–2026 R&D and technology programs from official company sources:

• Medtronic plc expanded its pulsed field ablation portfolio with the PulseSelect™ and Affera™ Sphere-9™ systems in FY2025–2026, achieving 71% US growth in Cardiac Ablation Solutions as hospital electrophysiology labs adopted PFA as the standard energy source for atrial fibrillation ablation procedures, reducing esophageal injury risk versus radiofrequency ablation.
• Johnson & Johnson MedTech initiated clinical trials for the OTTAVA™ Robotic Surgical System in general surgery in 2025, pursuing FDA clearance for a platform designed to address the broader soft-tissue surgical robotics market beyond the urology-focused da Vinci ecosystem.
• Abbott Laboratories advanced the Volt™ pulsed field ablation catheter into a global pivotal clinical trial in 2025, with the system featuring a variable-geometry design intended to improve contact and energy delivery consistency across pulmonary vein anatomy variations in atrial fibrillation patients.
• GE HealthCare Technologies expanded its AI-powered Edison™ health platform to 100 FDA-listed AI authorizations by July 2025, with new algorithms targeting automated cardiac chamber quantification, lung nodule characterization, and radiology workflow prioritization for emergency imaging queues.
• Siemens Healthineers continued deployment of Photon Counting CT technology across North American and European hospital networks in 2025, delivering 4x improvement in spatial resolution versus conventional CT detectors for pulmonary embolism, coronary artery calcium scoring, and hepatic lesion characterization applications.
• Stryker Corporation invested in next-generation Mako™ robotic-arm software updates in 2025, integrating AI-powered haptic feedback calibration that reduces intraoperative bone preparation time and improves implant positioning accuracy in knee arthroplasty procedures across installed base systems.
• Boston Scientific Corporation advanced the FARAPULSE™ pulsed field ablation system's procedural efficiency profile in 2025, with physician adoption data confirming median procedure times of under 60 minutes for pulmonary vein isolation — a 40% reduction versus radiofrequency ablation benchmark times — driving rapid account conversion across electrophysiology centers.
• Becton, Dickinson and Company expanded its BD Libertas™ wearable injector clinical development partnerships in 2025, with multiple pharmaceutical company collaborators advancing large-volume subcutaneous biologic drug candidates through Phase 2–3 trials using BD's drug-device combination platform, targeting oncology and immunology indications.

Industry Signal: MRFR identifies the convergence of pulsed field ablation energy delivery, AI-integrated imaging interpretation, and robotics-assisted surgical planning as the overarching innovation direction reshaping competitive differentiation in the Medical Devices Market, with vendors achieving clinical procedural efficiency gains and measurable patient outcome improvements positioned to command premium implant and capital equipment pricing through the forecast period.